# A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

> **NCT02017171** · PHASE3 · COMPLETED · sponsor: **Alessandro Doria** · enrollment: 530 (actual)

## Conditions studied

- Diabetic Nephropathies
- Coronary Artery Disease

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02017171
- **Lead sponsor:** Alessandro Doria
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-07-15
- **Final completion:** 2019-08-31
- **Target enrollment:** 530 (ACTUAL)
- **Last updated:** 2020-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017171, "A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02017171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*